|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Masashi_Miyamoto
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:formerName
|
gptkb:Kyowa_Hakko_Kirin
|
|
gptkbp:founded
|
1949
|
|
gptkbp:headquartersLocation
|
gptkb:Tokyo,_Japan
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:mergedInto
|
gptkb:Kyowa_Hakko_and_Kirin_Pharma_(2008)
|
|
gptkbp:notableProduct
|
gptkb:Crysvita
gptkb:Gran
gptkb:Nourianz
gptkb:Poteligeo
|
|
gptkbp:numberOfEmployees
|
over 5,000
|
|
gptkbp:parentCompany
|
gptkb:Kirin_Holdings_Company,_Limited
|
|
gptkbp:products
|
oncology drugs
biopharmaceuticals
therapeutic antibodies
immunology drugs
nephrology drugs
|
|
gptkbp:researchInterest
|
immunology
oncology
nephrology
central nervous system diseases
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4151
|
|
gptkbp:subsidiary
|
gptkb:Kirin_Holdings
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.kyowakirin.com/
|
|
gptkbp:bfsParent
|
gptkb:Orchard_Therapeutics
gptkb:PhRMA
gptkb:WuXi_Biologics
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kyowa Kirin
|